Literature DB >> 15717050

The design of clinical trials for cell transplantation into the central nervous system.

Pierre Cesaro1.   

Abstract

Mesh:

Year:  2004        PMID: 15717050      PMCID: PMC534955          DOI: 10.1602/neurorx.1.4.492

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


× No keyword cloud information.
  42 in total

Review 1.  Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD).

Authors:  G L Defer; H Widner; R M Marié; P Rémy; M Levivier
Journal:  Mov Disord       Date:  1999-07       Impact factor: 10.338

Review 2.  Cell replacement therapies for central nervous system disorders.

Authors:  A Björklund; O Lindvall
Journal:  Nat Neurosci       Date:  2000-06       Impact factor: 24.884

3.  Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF.

Authors:  A C Bachoud-Lévi; N Déglon; J P Nguyen; J Bloch; C Bourdet; L Winkel; P Rémy; M Goddard; J P Lefaucheur; P Brugières; S Baudic; P Cesaro; M Peschanski; P Aebischer
Journal:  Hum Gene Ther       Date:  2000-08-10       Impact factor: 5.695

Review 4.  Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson's disease and proposed criteria for use of sham surgery controls.

Authors:  R L Albin
Journal:  J Med Ethics       Date:  2002-10       Impact factor: 2.903

5.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

Authors:  C R Freed; P E Greene; R E Breeze; W Y Tsai; W DuMouchel; R Kao; S Dillon; H Winfield; S Culver; J Q Trojanowski; D Eidelberg; S Fahn
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

6.  Bilateral human fetal striatal transplantation in Huntington's disease.

Authors:  R A Hauser; S Furtado; C R Cimino; H Delgado; S Eichler; S Schwartz; D Scott; G M Nauert; E Soety; V Sossi; D A Holt; P R Sanberg; A J Stoessl; T B Freeman
Journal:  Neurology       Date:  2002-03-12       Impact factor: 9.910

7.  Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.

Authors:  P Piccini; D J Brooks; A Björklund; R N Gunn; P M Grasby; O Rimoldi; P Brundin; P Hagell; S Rehncrona; H Widner; O Lindvall
Journal:  Nat Neurosci       Date:  1999-12       Impact factor: 24.884

8.  Motor and cognitive improvements in patients with Huntington's disease after neural transplantation.

Authors:  A C Bachoud-Lévi; P Rémy; J P Nguyen; P Brugières; J P Lefaucheur; C Bourdet; S Baudic; V Gaura; P Maison; B Haddad; M F Boissé; T Grandmougin; R Jény; P Bartolomeo; G Dalla Barba; J D Degos; F Lisovoski; A M Ergis; E Pailhous; P Cesaro; P Hantraye; M Peschanski
Journal:  Lancet       Date:  2000-12-09       Impact factor: 79.321

9.  Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease.

Authors:  P Brundin; O Pogarell; P Hagell; P Piccini; H Widner; A Schrag; A Kupsch; L Crabb; P Odin; B Gustavii; A Björklund; D J Brooks; C D Marsden; W H Oertel; N P Quinn; S Rehncrona; O Lindvall
Journal:  Brain       Date:  2000-07       Impact factor: 13.501

Review 10.  Cell transplantation for stroke.

Authors:  Sean I Savitz; Daniel M Rosenbaum; Jonathan H Dinsmore; Lawrence R Wechsler; Louis R Caplan
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

View more
  1 in total

1.  Co-transplantation of GDNF-overexpressing neural stem cells and fetal dopaminergic neurons mitigates motor symptoms in a rat model of Parkinson's disease.

Authors:  Xingli Deng; Yuanxin Liang; Hua Lu; Zhiyong Yang; Ru'en Liu; Jinkun Wang; Xiaobin Song; Jiang Long; Yu Li; Deqiang Lei; Zhongtang Feng
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.